Medical/Pharmaceuticals
Renuka Iyer, MD, Named New Chief Medical Officer for National Comprehensive Cancer Network (NCCN)
Acclaimed oncologist from Roswell Park Comprehensive Cancer Center to help lead nonprofit responsible for gold standard guidelines that define and advance cancer care worldwide. PLYMOUTH MEETING, Pa., Dec. 4, 2025 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of ...
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics
Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets and China Collaboration designed to accelerate and expand the development of synergistic combinations with CR-001 and ADCs, including SKB105 CR...
Menarini Asia-Pacific Expands Production Facilities, Strengthening Indonesia's Role as Regional Manufacturing Hub
* Menarini announces the expansion of MiLab facilities in Cikarang, including a new warehouse andenhanced production facility to meet growing export demands. * Another milestone includes the projected export of up to 700,000 units of Dermatix products toChina alone this year. * The event hig...
American Society of Clinical Oncology (ASCO) announces dates for 2026 ASCO Breakthrough and begins accepting submissions for novel oncology research
Global oncology society calls for abstract submissions for research that is shaping the future of cancer care in advance of annualAsia-Pacific meeting in Singapore SINGAPORE, Dec. 4, 2025 /PRNewswire/ -- The American Society of Clinical Oncology (ASCO) today launched its call for abstracts for i...
Emerald Clinical Appoints Luke Gill as Vice President, Global Head of Oncology, Medical & Scientific Affairs
Accomplished biotech and CRO leader brings 25+ years of global oncology drug
development and operational excellence to propel Emerald's continued growth.
SINGAPORE, Dec. 3, 2025 /PRNewswire/ -- Emerald
XPOVIO® Approved in Hong Kong for Two Additional Indications in Multiple Myeloma and Diffuse Large B-Cell Lymphoma
- XPOVIO® (selinexor) has received approvals for three indications in Hong Kong . These include its previous approval as the treatment for multiple myeloma (MM) when used together with dexamethasone (Xd), and its recent approvals as a monotherapy for relapsed or refractory diffuse large B-cell lym...
S3 Connected Health Receives Frost & Sullivan's 2025 Global Company of the Year Recognition for Excellence in Medical Device Connectivity
Recognized for pioneering advancements that redefine medical device
connectivity, accelerate home-based care, and deliver transformative value
across global healthcare ecosystems.
SAN ANTONIO, Dec. 3, 2025 /PRNewswire/ -- Frost & Sullivan
World-Leading Microsurgeon Professor J.P. Hong Joins MediThinQ as CMO, Marking Strong Validation for Next-Generation Digital Microsurgery
SINGAPORE, Dec. 3, 2025 /PRNewswire/ -- MediThinQ
THE U.S. POINTER STRUCTURED HEALTHY LIFESTYLE PROGRAM -- PREVIOUSLY SHOWN TO IMPROVE COGNITION -- MAY ALSO IMPROVE SLEEP APNEA, BLOOD PRESSURE REGULATION, AND COGNITIVE RESILIENCE
- Two-year lifestyle intervention "recipe" tested in three NIH-funded ancillary
studies -
Key Takeaways
* Findings from three NIA-funded ancillary studies to the U.S. POINTER trial
TraceLink Announces 2025 Corporate Grant Recipients Driving Global Community Impact
Through this annual program, TraceLink champions global health equity, community resilience, and shared purpose Summary TraceLink announced the eight global nonprofit recipients of its 2025 corporate grant program, supporting organizations in the U.S.,India, and Spain and providing volunteer opp...
Frost & Sullivan: Health Recovery Solutions Receives the 2025 North American Customer Value Leadership Recognition for Excellence in Patient-Centered Care Delivery
Frost & Sullivan recognizes Health Recovery Solutions for delivering adaptable,
outcomes-driven, technology-enabled longitudinal care models
SAN ANTONIO, Dec. 2, 2025 /PRNewswire/ -- Frost & Sullivan
Neusoft Medical Systems Unveils World's First 8cm Wide-Coverage Photon-Counting CT and Other Premium Innovations at RSNA 2025
CHICAGO, Dec. 2, 2025 /PRNewswire/ -- Neusoft Medical Systems Co., Ltd. ("Neusoft Medical"), a global leader in medical imaging, is showcasing its comprehensive portfolio of intelligent healthcare innovations at the Radiological Society ofNorth America (RSNA) 2025 annual meeting. The highlight o...
Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy
SHANGHAI and HONG KONG, Dec. 2, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dise...
Accord Healthcare Announces Launch of Denosumab∇ - Second Biosimilar in Bone Health
∇ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. LONDON, Dec. 2, 2025 /PRNewswire/ -- Accord Healthcare today announced the launch of Osvyrti (denosumab), a biosimilar to Prolia® (Amgen), and Jubereq (denosumab), a biosimilar to...
Amaran Biotech's Vaccine Adjuvant AB-801 Receives FDA Drug Master File (DMF) Filing Acknowledgement
HSINCHU, Dec. 2, 2025 /PRNewswire/ -- Amaran Biotech, a next-generation Contract Development and Manufacturing Organization (CDMO), announced that its self-developed, GMP-grade high-purity vaccine adjuvantAB-801 has received an Acknowledgement Letter from the U.S. Food and Drug Administration (FD...
Chula's Deep GI: AI Revolutionizes Gastrointestinal Cancers Detection
BANGKOK, Dec. 2, 2025 /PRNewswire/ -- The Faculty of Medicine
Lynk Pharmaceuticals Announces FDA IND Approval of Its Allosteric TYK2 Inhibitor LNK01006
HANGZHOU, China and SHANGHAI and BOSTON, Dec. 2, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on developing innovative therapies for immune and inflammatory diseases, today ann...
Ziwig Endotest®: Scientific Validation Published in NEJM Evidence
LYON, France, Dec. 2, 2025 /PRNewswire/ -- NEJM Evidence, a journal of the New England Journal of Medicine Group, has published an article titled "Validation of a Saliva microRNA Signature for Endometriosis," dedicated to the saliva-based diagnostic test developed by Ziwig. The publication repor...
CQ Medical® Expands Radiation Therapy Portfolio With Bionix Business Unit Acquisition
AVONDALE, Pa., Dec. 2, 2025 /PRNewswire/ -- CQ Medical, the global leader in patient radiotherapy positioning and healthcare innovation, is proud to announce the acquisition of Bionix's Radiation Therapy business unit, marking an expansion of its patient positioning and marking product portfolio....
Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI
SOLAIRIA-1 and SOLAIRIA-2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains inadequately controlled on current therapies These are the first global Phase 3 studies of a long-acting anti-TSLP antibody, marking a pivotal step as GB-0895 advances the pro...
Week's Top Stories
Most Reposted
Agoda Releases AI Developer Report 2026: Agentic AI Adoption Outpaces Enterprise Readiness Across Southeast Asia and India
[Picked up by 294 media titles]
2026-09-24 10:30Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 278 media titles]
2026-09-29 09:00HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 278 media titles]
2026-09-28 23:04Malaysia Calls for Shift from Halal-Certified to Halal-Competitive as ASEAN Targets USD5 Trillion Global Halal Economy
[Picked up by 277 media titles]
2026-09-25 14:45DOKU Names Himelda Renuat CEO as Ant International's Antom Deepens Strategic Investment in Indonesia's Payments Leader
[Picked up by 274 media titles]
2026-09-24 10:00